Natera Inc (NTRA) - Total Liabilities
Based on the latest financial reports, Natera Inc (NTRA) has total liabilities worth $840.38 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Natera Inc (NTRA) equity growth momentum to track the company's year-over-year net asset growth rate.
Natera Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Natera Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Natera Inc to measure how efficiently the company converts operating cash flow to free cash.
Natera Inc Competitors by Total Liabilities
The table below lists competitors of Natera Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $753.82 Million |
|
Erste Group Bank AG
VI:EBS
|
Austria | €409.72 Billion |
|
Ameriprise Financial Inc
NYSE:AMP
|
USA | $178.24 Billion |
|
Sysco Corporation
NYSE:SYY
|
USA | $24.84 Billion |
|
Haleon plc
NYSE:HLN
|
USA | $16.12 Billion |
|
Legrand SA
PA:LR
|
France | €9.69 Billion |
|
LEGRAND UNSP.ARD 1/5 EO 4
F:LRC0
|
Germany | €10.42 Billion |
|
ArcelorMittal SA
AS:MT
|
Netherlands | €41.06 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Natera Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Natera Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Natera Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Natera Inc (2012–2025)
The table below shows the annual total liabilities of Natera Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $795.62 Million | +70.99% |
| 2024-12-31 | $465.31 Million | -31.20% |
| 2023-12-31 | $676.37 Million | -1.79% |
| 2022-12-31 | $688.73 Million | +18.10% |
| 2021-12-31 | $583.18 Million | +30.78% |
| 2020-12-31 | $445.92 Million | +46.71% |
| 2019-12-31 | $303.94 Million | +28.79% |
| 2018-12-31 | $236.01 Million | +24.74% |
| 2017-12-31 | $189.20 Million | +81.56% |
| 2016-12-31 | $104.20 Million | +29.49% |
| 2015-12-31 | $80.47 Million | -72.72% |
| 2014-12-31 | $294.96 Million | +27.56% |
| 2013-12-31 | $231.23 Million | +66.47% |
| 2012-12-31 | $138.90 Million | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more